Hester Biosciences Limited — Q4 FY26
Hester Biosciences reported a strong Q4 FY26 with standalone revenue growing 22% YoY and PAT surging 174% YoY, driven by a 41% YoY jump in poultry healthcare revenue.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
PPR and Goatpox immunization programs expected from February 2026
Government immunization programs for PPR and goatpox (LSD) are expected to commence from February 2026, improving animal health division momentum in Q4.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY26
Remaining CWIP to be capitalized over coming months
The remaining capital work in progress (₹182 Cr) is expected to be capitalized in the coming months, adding capacity.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1